Compare GLSI & SSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLSI | SSP |
|---|---|---|
| Founded | 2006 | 1878 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.1M | 264.6M |
| IPO Year | 2020 | 1998 |
| Metric | GLSI | SSP |
|---|---|---|
| Price | $21.90 | $3.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $50.00 | $6.95 |
| AVG Volume (30 Days) | 130.9K | ★ 827.2K |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,150,585,000.00 |
| Revenue This Year | N/A | $8.34 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.78 | $2.04 |
| 52 Week High | $34.10 | $5.39 |
| Indicator | GLSI | SSP |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 49.83 |
| Support Level | $21.16 | $2.09 |
| Resistance Level | $29.89 | $3.75 |
| Average True Range (ATR) | 2.17 | 0.19 |
| MACD | 0.08 | 0.06 |
| Stochastic Oscillator | 61.02 | 82.73 |
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers.
The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.